<DOC>
	<DOCNO>NCT01670513</DOCNO>
	<brief_summary>Subjects clinical diagnosis plaque psoriasis 10 % 20 % body surface area affect enrolled study .</brief_summary>
	<brief_title>A Phase 2 Dose Ranging , Evaluator-Blinded Study Evaluate Safety Topical IDP-118</brief_title>
	<detailed_description>Approximately 60 subject clinical diagnosis moderate severe psoriasis ( define least 10 % - 20 % treatable Body Surface Area ( BSA ) Investigator 's Global Evaluation ( IGE ) 3 4 baseline ( moderate severe ) enrol study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female race , 18 65 ( inclusive ) year age . Freely give verbal write informed consent obtain subject . Clinical diagnosis psoriasis Screening Baseline visit At least 10 % 20 % total treatable BSA involvement , Investigator 's Global Evaluation score 3 4 ( moderate severe ) scale 0 5 Good general health determine Investigator base subject 's medical history physical examination , Screening hematology , serum chemistry , urinalysis laboratory value within normal range limit . Presence psoriasis previously treat prescription medication prior Screening visit nonresponsive corticosteroid treatment , determine Investigator . Presence concurrent skin condition could interfere evaluation study drug , determine Investigator . History adrenal disease Female pregnant , nurse infant , plan pregnancy study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>